Please assess the completion status of the following clinical trial:

Trial Title: Initial Combination With Pioglitazone Study (0431-064)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
General Inclusion Criteria:~* Patients ≥18 years old with Type 2 Diabetes Mellitus (a specific type of diabetes)~General Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis~* Patient was on antihyperglycemic agent therapy (oral or insulin) within the prior 4 months~* Patient was on \>4 weeks (cumulatively) of antihyperglycemic therapy (oral or insulin) over the prior 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
- 2 (Type: ACTIVE_COMPARATOR): sitagliptin 100 mg placebo q.d./pioglitazone 30 mg q.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).